Summary

US Antidepressant Drugs Market is valued approximately USD 4.62 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.68% over the forecast period 2024-2032. Antidepressant drugs are medications designed to alleviate the symptoms of depression, a mental health disorder characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities. These drugs work by altering the balance of certain chemicals in the brain, known as neurotransmitters, which are believed to influence mood and emotional state Furthermore pharmaceutical companies continue to invest in research and development of new antidepressant drugs with improved efficacy and fewer side effects. These innovations contribute to market growth as healthcare providers and patients seek better treatment options in US Antidepressant Drugs Market.


The US Antidepressant Drugs Market is driven by increasing awareness and acceptance of mental health conditions, leading more individuals to seek treatment for depression and anxiety disorders. This growing acceptance has reduced the stigma associated with mental illness, encouraging people to seek help and contributing to a higher demand for antidepressant medications. In addition, the prevalence of depression and anxiety is on the rise, partly due to factors such as social isolation, economic uncertainty, and other stressors. As a result, there's a larger pool of patients in need of treatment, which is driving the growth of the antidepressant drugs market. Additionally, advancements in pharmaceutical research and development have led to the introduction of new antidepressant drugs with improved efficacy and fewer side effects. These innovations appeal to both healthcare providers and patients, driving market growth as they seek better treatment options, resulting in market growth. However, side effects and safety concerns as well as availability of alternative treatments is going to impede the overall demand for the market during the forecast period 2024-2032.


Major market player included in this report are:
Pfizer Inc.
Bristol-Myers Squibb
Eli Lilly and Company
Mylan N.V.
Amneal Pharmaceutical Inc
Avet Pharmaceuticals Inc.
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others

By Depressive Disorders
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Antidepressant Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Antidepressant Drugs Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Product
2.2.2. By Depressive Disorder
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Antidepressant Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Antidepressant Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Antidepressant Drugs Market Size & Forecasts by Product 2022-2032
5.1. Tricyclic Antidepressants
5.2. Selective Serotonin Reuptake Inhibitors
5.3. Serotonin Norepinephrine Reuptake Inhibitors
5.4. Monoamine Oxidase Inhibitors
5.5. Serotonin Antagonist and Reuptake Inhibitors
5.6. Others
Chapter 6. US Antidepressant Drugs Market Size & Forecasts by Depressive Disorder 2022-2032
6.1. Major Depressive Disorder
6.2. Obsessive-Compulsive Disorder
6.3. Generalized Anxiety Disorder
6.4. Panic Disorder
6.5. Others
Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Pfizer Inc
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Market Strategies
7.3.2. Bristol-Myers Squibb
7.3.3. Eli Lilly and Company
7.3.4. Mylan N.V.
7.3.5. Amneal Pharmaceutical Inc
7.3.6. Avet Pharmaceuticals Inc.
7.3.7. Company 7
7.3.8. Company 8
7.3.9. Company 9
7.3.10. Company 10
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes